Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Remus PharmaceuticalsNSE:REMUS -1.49%55 EV-to-EBIT is 17.52 as of Aug. 19, 2026, which is 52% below its 10-year median of 36.49. GuruFocus rates NSE:REMUS with a GF Score™ of 55/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 96 Medical Distribution companies, Remus Pharmaceuticals ranks worse than 70.83% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Remus Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2026 was ₹6,016 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Remus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹606 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Remus Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's EV-to-EBIT falls into.
Remus Pharmaceuticals's current Enterprise Value is ₹10,622 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Remus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹606 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Remus Pharmaceuticals (NSE:REMUS) has a EV-to-EBIT of 17.52 as of Aug. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Remus Pharmaceuticals and its competitors. This is 52% below median its historical median of 36.49. Over the past decade, Remus Pharmaceuticals' EV-to-EBIT has ranged from 9.95 to 243.49. According to the industry distribution chart, Remus Pharmaceuticals ranks #68 out of 96 companies in the Medical Distribution industry, placing it in the top 70.8%.
Is Remus Pharmaceuticals' EV-to-EBIT too high?
Remus Pharmaceuticals' current EV-to-EBIT of 17.52 is 52% below median its 10-year median of 36.49. Over the past 10 years, this metric has ranged from a low of 9.95 to a high of 243.49. The Medical Distribution industry median EV-to-EBIT is 11.81. Remus Pharmaceuticals' value of 17.52 is 48.4% above this industry median. Based on the distribution chart, Remus Pharmaceuticals ranks #68 out of 96 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Remus Pharmaceuticals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' EV-to-EBIT compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #68 out of 96 companies for EV-to-EBIT. This places Remus Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 11.81. Remus Pharmaceuticals' value of 17.52 is 48.4% above this benchmark. Historically, Remus Pharmaceuticals' own EV-to-EBIT has ranged from 9.95 to 243.49 over the past decade. While the company's 10-year median is 36.49 vs. the industry median of 11.81, Remus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.81, based on 96 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Remus Pharmaceuticals's current EV-to-EBIT of 17.52 is 48.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Remus Pharmaceuticals and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current EV-to-EBIT is 17.52, which is 52% below median its own 10-year median of 36.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹893.80 — trading 56.8% below its estimated fair value. The current EV-to-EBIT is 17.52, which is 52% below median its 10-year median of 36.49 and 48.4% above the Medical Distribution industry median of 11.81. Remus Pharmaceuticals' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current EV-to-EBIT is 17.52 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹893.80 is trading 56.8% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
EV-to-EBIT: 17.52 (52% below median its 10-year median of 36.49)
GF Value™: ₹2,071.36 vs. price of ₹893.80 (56.8% below fair value)
Industry Position: 48.4% above the Medical Distribution median (#68 of 96)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
55GF Score
Get the complete analysis for NSE:REMUS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
